Sector News

Pfizer axing neuroscience jobs, but seeks new VC fund

January 9, 2018
Life sciences

Big Pharma Pfizer, on the eve of J.P. Morgan, the biggest biopharma dating event on the year, will cut around 300 jobs and a number of earlier stage projects from its neuroscience pipeline.

The move will see it back out of work in Alzheimer’s and Parkinson’s disease, two notoriously difficult areas for the industry, especially the former, which has not seen any real R&D advance in 15 years.

In a statement on Friday, Pfizer said it will be redirecting funds “to those areas where we have strong scientific leadership and that will allow us to provide the greatest impact for patients,” adding that its total spending on R&D will not change, which amounted to around $8 billion last year.

The ax will fall predominately in Cambridge and Andover, Massachusetts, and in Groton, Connecticut, with about 100 expected at each site.

Those projects up for the chop are preclinical, early and midstage clinical programs primarily focused on Alzheimer’s and Parkinson’s, but Pfizer could outlicense these, or cofund them, through venture investments.

It has a host of meds in these areas, including a phase 2 dopamine 1 activator for Parkinson’s, as well as four phase 1 Alzheimer’s drugs that include PF-05251749 and PF-06648671, a γ-secretase modulator.

This comes after many other Big Pharmas, and smaller biotechs, have failed to move the needle on Alzheimer’s disease drugs in R&D, making ROI on these types of projects precisely zero.

The changes will not hit work on its pain treatments Lyrica and tanezumab, or research into drugs for rare neurological diseases, the Big Pharma stressed.

But the company did say it will set up a neuroscience venture fund “to support continued efforts to advance the field,” although details were not shared. More should come of this later in the year, it adds, and will be focused on external projects.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

March 19, 2023

Ferring Pharmaceuticals’ 1st in class C.diff Treatment, Rebyota, experiences a positive early launch ahead of potential competition

Life sciences

With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.

March 19, 2023

UCB enters drug discovery collaboration with Aitia

Life sciences

Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.

March 19, 2023

Novo, Medtronic add $25M in fuel to FIRE1 and its heart failure monitoring device

Life sciences

Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.

How can we help you?

We're easy to reach